Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.906
https://www.valueinhealthjournal.com/article/S1098-3015(14)02836-8/fulltext
Title :
Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)02836-8&doi=10.1016/j.jval.2014.08.906
First page :
A399
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
418